Large Liver Mass Found in 53-Year-Old Man

Poll

A 53-year-old man presents with a large hepatic mass. After further evaluation, a biopsy is performed. What is your diagnosis?

A 53-year-old man presents with a large hepatic mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Hepatic adenoma
B. Intrahepatic cholangiocarcinoma
C. Biliary cirrhosis
D. Bile duct adenoma
Recent Videos
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Related Content
Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma

Roman Fabbricatore
October 18th 2024
Article

Data from the phase 3 SPOTLIGHT trial and the phase 3 GLOW trial supported the approval of zolbetuximab plus chemotherapy in this indication.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

sNDA of Fruquintinib Combo Withdrawn in China for Second-Line Gastric/GEJ Cancer

sNDA of Fruquintinib Combo Withdrawn in China for Second-Line Gastric/GEJ Cancer

Ariana Pelosci
August 30th 2024
Article

Second-line fruquintinib plus paclitaxel did not sustain sufficient efficacy for patients with advanced gastric or GEJ adenocarcinoma to support approval in China.

The addition of neoadjuvant S-1 also reduced the risk of death compared with adjuvant therapy alone in the phase 3 PRODIGY trial.

S-1/Chemo Regimen Improves PFS in Resectable Advanced Gastric Cancer

Gina Mauro
August 28th 2024
Article

The addition of neoadjuvant S-1 also reduced the risk of death compared with adjuvant therapy alone in the phase 3 PRODIGY trial.

Enrollment will soon begin for the dose-expansion portion of the ongoing phase 1 trial assessing EO-3021 in CLDN18.2-positive tumors.

EO-3021 Elicits Responses in Advanced CLDN18.2+ Gastric/GEJ Cancer

Russ Conroy
August 12th 2024
Article

Enrollment will soon begin for the dose-expansion portion of the ongoing phase 1 trial assessing EO-3021 in CLDN18.2-positive tumors.

Combining evorpacept with trastuzumab, ramucirumab, and paclitaxel appeared to be well tolerated among patients enrolled on the phase 2 ASPEN-06 trial.

Evorpacept Combo Improves Responses in Pretreated HER2+ Gastric Cancer

Russ Conroy
August 7th 2024
Article

Combining evorpacept with trastuzumab, ramucirumab, and paclitaxel appeared to be well tolerated among patients enrolled on the phase 2 ASPEN-06 trial.